Asset Details
Do you wish to reserve the book?
Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers
Do you wish to request the book?
Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers
2015
Overview
Use of a new generation anti-sense oligonucleotide to target exon skipping in multiple organ systems in two mouse models of muscular dystrophy
Antisense oligonucleotides (AONs) hold promise for therapeutic correction of many genetic diseases via exon skipping, and the first AON-based drugs have entered clinical trials for neuromuscular disorders
1
,
2
. However, despite advances in AON chemistry and design, systemic use of AONs is limited because of poor tissue uptake, and recent clinical reports confirm that sufficient therapeutic efficacy has not yet been achieved. Here we present a new class of AONs made of tricyclo-DNA (tcDNA), which displays unique pharmacological properties and unprecedented uptake by many tissues after systemic administration. We demonstrate these properties in two mouse models of Duchenne muscular dystrophy (DMD), a neurogenetic disease typically caused by frame-shifting deletions or nonsense mutations in the gene encoding dystrophin
3
,
4
and characterized by progressive muscle weakness, cardiomyopathy, respiratory failure
5
and neurocognitive impairment
6
. Although current naked AONs do not enter the heart or cross the blood-brain barrier to any substantial extent, we show that systemic delivery of tcDNA-AONs promotes a high degree of rescue of dystrophin expression in skeletal muscles, the heart and, to a lesser extent, the brain. Our results demonstrate for the first time a physiological improvement of cardio-respiratory functions and a correction of behavioral features in DMD model mice. This makes tcDNA-AON chemistry particularly attractive as a potential future therapy for patients with DMD and other neuromuscular disorders or with other diseases that are eligible for exon-skipping approaches requiring whole-body treatment.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ 13/106
/ 13/109
/ 38/77
/ 82/58
/ Animals
/ Blood-Brain Barrier - metabolism
/ DNA
/ Exons
/ letter
/ Mice
/ Microscopy, Electron, Transmission
/ Muscle, Skeletal - drug effects
/ Muscle, Skeletal - metabolism
/ Muscles
/ Muscular Dystrophy, Duchenne
/ Mutation
/ Neurons
/ Oligodeoxyribonucleotides, Antisense - metabolism
/ Oligodeoxyribonucleotides, Antisense - pharmacology
/ Rodents
